August 29th 2025
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.
Disposable Applications in Demand by Biopharma
November 1st 2013Data from BioPlan Associates' 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production suggest that the interest in disposable devices has begun to extend to biopharma operations beyond basic single-use bags and connectors.
The correlation between limulus amebocyte lysate (LAL) assay and rabbit pyrogen test (RPT) targeting recombinant human epidermal growth factor (rhEGF) as active molecule was assessed.